FDA Updates Warnings for Additional Menopausal Hormone Therapies

The FDA has revised labeling for three more estradiol transdermal patches used in menopausal hormone therapy, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia. This follows similar changes earlier in 2026, reflecting updated understanding of MHT risks and benefits. This adjustment impacts patient and physician decision-making regarding MHT use.